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B reast cancer screening programs using mammog-raphy have greatly increased the detection of duc-
tal carcinoma in situ (DCIS) [1].  Nowadays,  approxi-
mately 20-25% of screening-detected breast cancers are 
DCIS [2 , 3].  DCIS is characterized by the proliferation 
of neoplastic ductal epithelial cells confined to the base-
ment membrane of mammary ducts [4].  Since DCIS 
does not have the ability to metastasize to regional 
lymph nodes,  axillary lymph node staging is theoreti-
cally not required.  However,  more than 20% of patients 
are upstaged to invasive disease on final pathology [5-9] 
because breast needle biopsies only sample limited parts 
of the lesions.
This underestimation causes problems regarding 
axillary lymph node metastases.  Sentinel node (SN) 
biopsy is currently performed for clinically node-nega-
tive invasive breast cancer to evaluate axillary lymph 
node status [10].  However,  SN biopsy for all patients 
with preoperatively diagnosed DCIS would lead to 
overtreatment; the incidence of SN metastases was 
found to be only 7.4% in a meta-analysis [11].  Although 
SN biopsy has lower morbidity than axillary resection,  
SN biopsy potentially causes several adverse effects such 
as lymphedema and motor neuropathy [12 , 13].  
Therefore,  unnecessary SN biopsy needs to be avoided.  
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Ductal carcinoma in situ (DCIS) of the breast has no potential to metastasize,  but over 20% of cases preopera-
tively diagnosed as DCIS are upstaged on final pathology.  The rates of upstaging and the predictors for invasion 
on final pathology were evaluated.  For 240 primary breast cancers,  radiological findings on mammography,  
ultrasonography,  and magnetic resonance imaging were investigated along with pathological and clinical infor-
mation.  Univariate and multivariate analyses were performed to identify predictors of potential invasion.  Of 
the 240 breast cancers,  68 (28.3%) showed invasion on final pathology,  and 5 (2.5%) had sentinel node metas-
tasis.  The multivariate analysis identified five independent predictors: non-mass lesions > 2.4 cm on ultraso-
nography (odds ratio [OR] 2.84,  95% confidence interval [CI] 1.02-7.95,  p = 0.047),  comedo-type histology 
(OR 6.89,  95% CI 1.89-25.08,  p < 0.01),  solid-type histology (OR 7.97,  95% CI 2.08-30.49,  p < 0.01),  palpable 
mass (OR 2.63,  95% CI 1.05-6.64,  p = 0.04),  and bloody nipple discharge (OR 4.61,  95% CI 1.20-17.66,  
p = 0.02).  These five predictors were associated with invasion on final pathology and may help select candidates 
for sentinel node biopsy.
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On the other hand,  if SN biopsy is not performed for all 
patients,  more than 20% of patients who have invasive 
disease will require SN biopsy later because invasive 
disease can lead to lymph node metastases.
To avoid both over- and undertreatments,  more 
accurate preoperative predictors are needed.  When 
DCIS is proven by a breast needle biopsy,  breast sur-
geons comprehensively estimate the probability of inva-
sive disease with clinical,  pathological and imaging 
examinations.
In Japan,  mammography,  ultrasonography,  and 
magnetic resonance imaging (MRI) are currently rou-
tinely preformed as useful preoperative imaging exam-
inations of the breast.  Contrast-enhanced MRI has been 
increasingly used,  because MRI has high sensitivity 
(90-94%) for detection [14 , 15] and is superior to mam-
mography and ultrasonography in demonstrating the 
extent and multi-centricity of breast cancer [14 , 16 , 17].  
There have been three reports so far in which the three 
modalities were all used as preoperative investigations 
to analyze predictors for invasive disease [9 , 18 , 19].  
However,  no report has examined which imaging size 
and features are the most useful to predict potential 
invasion.  Therefore,  in this single-institute retrospec-
tive study,  the radiological sizes and features of DCIS on 
mammography,  ultrasonography and MRI,  in addition 
to pathology and clinical examinations,  were analyzed 
in order to determine which modality has features that 
can accurately identify patients at higher risk of invasive 
disease.
Patients and Methods
Patient selection. The subjects were patients with 
a preoperative needle-biopsy diagnosis of DCIS who 
underwent breast surgery between January 2007 and 
April 2009 at the Cancer Institute Hospital,  Tokyo,  
Japan.  Inclusion criteria were as follows: 1) mammog-
raphy,  ultrasonography,  and MRI procedures were all 
performed to evaluate primary tumor before surgery,  
and 2) patients were clinically and ultrasonographically 
node-negative before surgery.  Exclusion criteria were as 
follows: 1) double cancer in the ipsilateral breast on 
final pathology,  2) neoadjuvant drug therapy for con-
tralateral breast cancer,  and 3) chemotherapy for another 
cancer before breast surgery.  This study was approved 
by the Institutional Review Board of the Cancer Institute 
Hospital (2015-1126).
Clinical examinations. Clinical examinations 
were performed twice,  at the initial visit and on the day 
before surgery.  If the findings were different,  those on 
the day before surgery were used for the study.  Palpable 
masses included indurations due to tumors.  Nipple 
discharge was classified as bloody,  serous,  or milky.
Imaging examinations. The Breast Imaging 
Reporting and Data System 4 th Edition [20] of the 
American College of Radiology was used to interpret 
the mammographic,  ultrasonographic,  and MRI imag-
ing features.  Mammographic features were classified as 
masses,  focal asymmetric densities,  distortions,  or 
calcifications.  The maximum size of the calcifications 
was also measured.  Mammography was performed 
with a Hologic Selenia system (Hitachi,  Tokyo,  Japan).  
Ultrasonographic features were classified as mass or 
non-mass abnormalities based on the Guideline for 
Breast Ultrasound: Management and Diagnosis 3rd 
Edition [21],  and the maximum size of non-mass 
abnormalities was measured.  Ultrasonography was per-
formed with the following devices: an Aplio SSA-700A 
(Toshiba,  Tokyo,  Japan),  a Nemio SSA-550A (Toshiba),  
an EUB-6000 (Hitachi),  or an EUB-5500 (Hitachi).  
MRI was performed on a 1.5-T system (Signa HDx 
1.5T,  GE Yokogawa Medical Systems,  Tokyo,  Japan),  
and dynamic contrast-enhanced MRI,  fat-suppressed 
T2-weight MRI,  and diffusion-weighted imaging with 
apparent diffusion coefficient maps were reviewed.  The 
features on MRI were classified as mass or non-mass 
enhancement,  and the maximum size of the non-mass 
enhancement was measured for the most suitable image 
condition.  When a patient had several imaging features,  
the higher priority one was chosen to avoid duplica-
tion.
Breast needle biopsy and histological evaluation of 
biopsy samples. Breast needle biopsy was performed 
under stereotactic or ultrasonography guidance.  
Stereotactic needle biopsy was mainly used for micro-
calcifications on mammograms using an 11-gauge 
Mammotome ST (Johnson & Johnson K.K.,  Tokyo,  
Japan).  The sampled specimens were radiologically 
checked for microcalcifications.  Ultrasonography-
guided biopsy was used for lesions that were visible on 
ultrasonography.  A 14-gauge Bard Monopty (Medicon,  
Inc.,  Osaka,  Japan),  10-gauge Bard Vacora (Medicon,  
Inc.),  or 11-gauge Mammotome EX (Johnson & 
Johnson K.K.) were used according to physician prefer-
ence.  The needle biopsy samples were stained with 
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hematoxylin and eosin,  and the histological structure 
and the nuclear grade were evaluated [22].
Histological examination of surgical samples.
Surgical materials from partial mastectomy were sec-
tioned at 0.5-cm intervals continuously from the nipple 
side to the periphery,  and each section was examined 
histologically [23].  Surgical materials from the mastec-
tomy were sectioned at 0.5- to 0.7-cm intervals contin-
uously from the nipple side to the periphery,  and sec-
tioning was performed to cover the entire tumor spread 
with macroscopic and radiologic examinations.  All of 
the sections were examined with hematoxylin and eosin 
staining [24].
SN biopsy procedure. Intraoperative lymphatic 
mapping of SNs was achieved by a radioactive colloid 
and/or blue dye of indigo carmine.  The radioisotope 
tracer used was 1.5 mCi/ml 99mTc-phytate.  The tracer 
was injected into the intradermal and subdermal space 
in the tumor area and the retro-tumoral space the day 
prior to surgery,  and lymphoscintigraphy was per-
formed one hour after injection.  Additionally,  2 to 3 ml 
of indigo carmine (Daiichi Sankyo,  Tokyo,  Japan) was 
injected in the peri-tumoral space or areola just before 
surgery.  SNs were identified using a hand-held gam-
ma-probe and blue dye staining.  Excised SNs were 
intraoperatively sectioned at 0.2-cm intervals and exam-
ined by frozen section with hematoxylin and eosin 
staining [25].
Statistical analysis. Preoperative information on 
clinical,  radiological,  and pathological characteristics 
was compared between pure DCIS and invasive disease 
on final pathology.  Regarding the calcification size on 
mammography,  and the non-mass lesion size on ultra-
sonography and on MRI,  the cutoff values were deter-
mined using Youden indexes,  which are defined as the 
maximum vertical distance between ROC curve and 
diagonal line.
The univariate and multivariate logistic regression 
analyses were used to investigate the relationships 
between the preoperative information and the presence 
of invasive disease on final pathology.  The biopsy 
methods and the number of specimens were excluded 
from the multivariate analysis,  because the choice of the 
needle size depended on the preference of the doctor 
who performed the biopsy.  The MRI findings of the 
cancer with and without bloody nipple discharge were 
compared.  The confidence intervals (CIs) were set at 
95%.  A p-value of < 0.05 (two-sided) was considered 
significant.  All analyses were conducted using the sta-
tistical software package Stata12 (StataCorp LP,  College 
Station,  TX,  USA).
Results
Patient characteristics. During the study period,  
264 patients were initially diagnosed as having DCIS by 
breast needle biopsies.  Of the 264 patients,  237 were 
ultimately included.  Of the 240 tumors (3 patients had 
bilateral tumors),  172 (71.7%) were pathologically con-
firmed as pure DCIS,  and 68 (28.3%) were found to be 
invasive on final pathology.  Table 1 shows the patient 
characteristics by invasive status on final pathology.
Predictors of invasive disease. The cutoff values 
were set at 2.1 cm,  2.4 cm and 4.0 cm for the calcifica-
tion size on mammography,  and non-mass lesion size 
on ultrasonography and on MRI,  respectively.  On the 
univariate analyses,  the following nine parameters were 
significant for invasive disease: palpable mass,  bloody 
nipple discharge,  mass or focal asymmetric density on 
mammography,  non-mass lesion > 2.4 cm in size on 
ultrasonography,  non-mass lesion > 4.0 cm in size on 
MRI,  mass lesion on MRI,  solid-type histology and 
comedo-type histology,  and high nuclear grade (Table 
2).
The multivariate analysis showed that the following 
5 factors were independent predictors: palpable mass 
(odds ratio [OR] 2.63,  95% CI 1.05-6.64,  p = 0.04),  
bloody nipple discharge (OR 4.61,  95% CI 1.20-17.66,  
p = 0.02),  comedo-type histology (OR 6.89,  95% CI 
1.89-25.08,  p < 0.01),  solid-type histology (OR 7.97,  
95% CI 2.08-30.49,  p < 0.01),  and non-mass lesion 
> 2.4 cm in size on ultrasonography (OR 2.84,  95% CI 
1.02-7.95,  p = 0.047) (Table 2).
MRI findings of tumors presenting bloody nipple 
discharge. Tumors presenting bloody nipple dis-
charge occupied wider lesions than those without 
(Table 3).  The rate of non-mass lesions (> 4.0 cm in 
size) on MRI was 52.2% in the group of cancers pre-
senting nipple discharge.  In addition,  almost all of the 
cancers (12 of 13 cases) with bloody nipple discharge 
had small invasions (< 0.5 cm in size) (median 0.1 cm,  
range 0.1-1.3 cm).
Axillary staging by SN biopsy. Of the 240 tumors,  
202 (81.2%) underwent SN biopsy (Table 1).  Of the 202 
tumors,  5 (2.5%) had positive SN(s),  and all five 
patients underwent additional axillary lymph node 
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Table 1　 Correlation between patient characteristics and invasive disease on ﬁnal pathology
Characteristic No. %
Invasive disease Pure DCIS
No. % No. %
No. of patients 240 100.0% 68 28.3% 172 71.7%
Age (years)
　Median (range) 49 (20-80) 49 (29-77) 49 (20-80)
Laterality
　Right 109 45.4% 30 27.5% 79 72.5%
　Left 131 54.6% 38 29.0% 93 71.0%
Tumor location
　Upper inner 53 22.1% 16 30.2% 37 69.8%
　Lower inner 19 7.9% 5 26.3% 14 73.7%
　Upper outer 119 49.6% 31 26.1% 88 73.9%
　Lower outer 41 17.1% 13 31.7% 28 68.3%
　Central 8 3.3% 3 37.5% 5 62.5%
Biopsy device
　14-gauge Bard Monopty 33 13.8% 15 45.5% 18 54.5%
　11-gauge Mammotome EX 195 81.3% 51 26.2% 144 73.8%
　10-gauge Bard Vacora 12 5.0% 2 16.7% 10 83.3%
Image guidance
　Stereotactic 164 68.3% 39 23.8% 125 76.2%
　Ultrasonography-guided 76 31.7% 29 38.2% 47 61.8%
No. of biopsy specimens
　Median (range) 5 (1-16) 5 (1-12) 5 (1-16)
Palpation
　No ﬁnding 176 73.3% 37 21.0% 130 79.0%
　Mass 64 26.7% 31 48.4% 33 51.6%
Nipple discharge
　None or milky 213 88.8% 53 24.9% 160 75.1%
　Serous 4 1.7% 2 50.0% 2 50.0%
　Bloody 23 9.6% 13 56.5% 10 43.5%
Mammography
　Calciﬁcation (≤2.1 cm) 91 37.9% 18 19.8% 73 80.2%
　Calciﬁcation (＞2.1 cm) 77 32.1% 24 31.2% 53 68.8%
　Distortion 14 5.8% 4 28.6% 10 71.4%
　Mass or FAD 30 12.5% 13 43.3% 17 56.7%
　No ﬁnding 28 11.7% 9 32.1% 19 67.9%
Ultrasonography
　No ﬁnding 97 40.4% 18 18.6% 79 81.4%
　Non-mass (≤2.4 cm) 58 24.2% 14 24.1% 44 75.9%
　Non-mass (＞2.4 cm) 54 22.5% 26 48.1% 28 51.9%
　Mass 31 12.9% 10 32.3% 21 67.7%
Magnetic resonance imaging
　No ﬁnding 68 28.3% 13 19.1% 55 80.9%
　Non-mass (≤4.0 cm) 96 40.0% 25 26.0% 71 74.0%
　Non-mass (＞4.0 cm) 54 22.5% 19 35.2% 35 64.8%
　Mass 22 9.2% 11 50.0% 11 50.0%
Histological structure
　Low papillary or ﬂat 55 22.9% 5 9.1% 50 90.9%
　Cribriform 62 25.8% 12 19.4% 50 80.6%
　Papillary 15 6.3% 4 26.7% 11 73.3%
　Solid 35 14.6% 18 51.4% 17 48.6%
　Comedo 73 30.4% 29 39.7% 44 60.3%
Nuclear grade
　1 156 65.0% 34 21.8% 122 78.2%
　2 59 24.6% 25 42.4% 34 57.6%
　3 25 10.4% 9 36.0% 16 64.0%
Breast surgery
　Total mastectomy 127 52.9% 49 38.6% 78 61.4%
　Partial mastectomy 113 47.1% 19 16.8% 94 83.2%
Axillary surgery
　None 36 15.0% 4 11.1% 32 88.9%
　Sentinel node biopsy only 197 82.1% 57 28.9% 140 71.1%
　Complete axillary resection 7 2.9% 7 100.0% 0 0.0%
DCIS,  ductal carcinoma in situ; FAD,  focal asymmetric density.
June 2017 Ultrasonographic Size Predicts Potential Invasion 237









Lower Upper Lower Upper
Age (years)
　≤40  1.00 (reference) 1.00 (reference)
　41-50  0.75 0.33  1.72 0.50 0.57 0.20  1.60 0.29
　≥51  0.76 0.34  1.71 0.51 0.52 0.19  1.44 0.21
Laterality
　Right  1.00 (reference) 1.00 (reference)
　Left  1.08 0.61  1.89 0.80 1.12 0.57  2.21 0.74
Tumor location
　Upper inner  1.00 (reference) 1.00 (reference)
　Lower inner  0.83 0.25  2.68 0.75 1.00 0.24  4.13 1.00
　Upper outer  0.81 0.40  1.67 0.57 0.81 0.34  1.94 0.64
　Lower outer  1.07 0.44  2.59 0.87 1.06 0.37  3.00 0.92
　Central  1.39 0.30  6.52 0.68 0.41 0.04  4.26 0.45
Palpation
　No ﬁnding  1.00 (reference) 1.00 (reference)
　Mass  3.53 1.92  6.49 ＜0.01＊＊ 2.63 1.05  6.64 0.04＊
Nipple discharge
　None,  milky or serous  1.00 (reference) 1.00 (reference)
　Bloody  3.83 1.59  9.23 ＜0.01＊＊ 4.61 1.20 17.66 0.02＊
Mammography
　Calciﬁcation (≤2.1 cm)  1.00 (reference) 1.00 (reference)
　Calciﬁcation (＞2.1 cm)  1.84 0.91  3.72 0.09 1.06 0.45  2.51 0.89
　Distortion  1.62 0.46  5.77 0.46 0.51 0.09  2.81 0.44
　Mass or FAD  3.10 1.28  7.53 0.01＊ 1.09 0.27  4.30 0.91
　No ﬁnding  1.92 0.75  4.95 0.18 0.38 0.08  1.74 0.21
Ultrasonography
　No ﬁnding  1.00 (reference) 1.00 (reference)
　Non-mass (≤2.4 cm)  1.40 0.63  3.08 0.41 1.17 0.46  3.00 0.75
　Non-mass (＞2.4 cm)  4.08 1.95  8.54 ＜0.01＊＊ 2.84 1.02  7.95 0.047＊
　Mass  2.09 0.84  5.19 0.11 0.76 0.15  3.72 0.66
Magnetic resonance imaging
　No ﬁnding  1.00 (reference) 1.00 (reference)
　Non-mass (≤4.0 cm)  1.49 0.70  3.18 0.30 0.82 0.32  2.09 0.67
　Non-mass (＞4.0 cm)  2.30 1.01  5.23 0.05＊ 0.62 0.19  1.98 0.42
　Mass  4.23 1.51 11.87 ＜0.01＊＊ 2.62 0.51 13.44 0.25
Histological structure
　Low papillary or ﬂat  1.00 (reference) 1.00 (reference)
　Cribriform  2.40 0.79  7.32 0.12 2.26 0.63  8.16 0.21
　Papillary  3.64 0.84 15.78 0.09 2.72 0.52 14.29 0.24
　Solid 10.59 3.41 32.89 ＜0.01＊＊ 7.97 2.09 30.49 ＜0.01＊＊
　Comedo  6.59 2.35 18.50 ＜0.01＊＊ 6.89 1.89 25.08 ＜0.01＊＊
Nuclear grade
　1  1.00 (reference) 1.00 (reference)
　2  2.64 1.39  5.01 ＜0.01＊＊ 1.44 0.60  3.46 0.42
　3  2.02 0.82  4.97 0.13 0.76 0.21  2.27 0.68
CI,  conﬁdence interval; FAD,  focal asymmetric density; ＊p＜0.05; ＊＊p＜0.01.
resection.  One of them had one metastatic node among 
the non-sentinel lymph nodes.  No metastasis was 
found in the patients with pure DCIS on final pathol-
ogy.  Two of the patients initially underwent axillary 
resection because axillary metastases were preopera-
tively proven by fine needle aspiration cytology.  These 2 
tumors both showed palpable masses,  comedo-type 
histology,  and a size > 4.0 cm on all three imaging 
examinations.
Discussion
The present study focuses on the utility of mam-
mography,  ultrasonography,  and MRI to predict the 
potential invasion of preoperatively diagnosed DCIS.  
Radiological findings including the tumor size (i.e.  cal-
cifications on mammography,  non-mass abnormalities 
on ultrasonography,  and non-mass enhancement on 
MRI) were used as variables for this analysis.  Five inde-
pendent predictors were identified: large non-mass 
abnormalities on ultrasonography (> 2.4 cm in size),  
histological structure (comedo type and solid type),  and 
clinical examination (palpable mass and bloody nipple 
discharge).
Thus,  ultrasonographic tumor size is one of the use-
ful predictors for potential invasion.  Lee et al.  reported 
that a lesion size > 2.0 cm on ultrasonography was a 
significant predictor [7].  Larger non-mass abnormali-
ties on ultrasonography could more likely contain inva-
sive disease than larger calcification on mammography 
and larger non-mass-like enhancement on MRI—find-
ings that mainly suggest intraductal components [7].  
Larger non-mass abnormalities on ultrasonography 
tend to indicate a thicker lesion,  which could be associ-
ated with invasive disease.  These radiological variations 
may be caused by the different expressions on each 
modality to reflect various characteristics of the tumors:  
for example,  the hardness and calcifications on mam-
mography,  the amount of tumor cells on ultrasonogra-
phy,  and the blood flow on MRI.  In the present study,  
the finding of a mass or focal asymmetric density on 
mammography and a mass on MRI were both signifi-
cant on the univariate analysis but not on the multivar-
iate analysis.  This is probably because a mass on imag-
ing examination was interrelated with a palpable mass.
With regard to the needle size,  DCIS can be diag-
nosed more correctly when using a 10- or 11-gauge 
needles than a 14-gauge needle.  This is partly because 
the 14-gauge needles tend to be used for radiologically 
clear lesions on ultrasonography,  and the 10- or 
11-gauge needles for radiologically obscure lesions such 
as tumors only presenting calcifications.
Clinical examination factors were found to be useful 
predictors for potential invasion.  A palpable mass was 
the common predictor in the previous reports 
[5 , 8 , 9 , 23 , 26].  Bloody nipple discharge has usually 
been considered to suggest a benign condition such as 
papilloma or ductal ectasia but also DCIS and DCIS 
with microinvasion [27].  The present study suggests 
that tumors presenting bloody nipple discharge are 
underestimated by needle biopsies because they histo-
logically have small invasion within the wide range of 
intraductal lesions.
The histological structures of intraductal compo-
nents are also common predictors.  In the present study,  
comedo-type and solid-type histology were both identi-
fied as independent predictors.  Comedo-type histology 
is a well-known predictor [28].  Osako et al.  and Han et 
al.  reported that solid type was also a significant pre-
dictor [23 , 29].  Solid-type intraductal lesions grow 
expansively in the mammary duct,  so they may poten-
tially have more chances to invade the stroma.
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Table 3　 Magnetic resonance imaging ﬁndings of tumors with and without bloody nipple discharge
Bloody nipple discharge
Present Absent Total
Finding No. % No. % No. %
　No ﬁnding  3  13.0  65  30.0  68 28.3
　Non-mass (≤4.0 cm)  4  17.4  92  42.4  96 40.0
　Non-mass (＞4.0 cm) 12  52.2  42  19.4  54 22.5
　Mass  4  17.4  18 　8.3  22 9.2
　Total 23 100.0 217 100.0 240 100.0
In the present study,  28.3% of the patients had inva-
sive disease on final pathology,  which is almost the 
same rate as in previous studies (20-41%) [5-9].  The 
rate of a positive SN biopsy was lower (2.5%) than that 
in the previous meta-analysis [11],  and all five patients 
who had SN metastases had invasive disease on final 
pathology.  The results of the American College of 
Surgeons Oncology Group Z0011 trial [30] suggested 
that not all lymph node metastases result in recurrence 
or systemic metastases.  Therefore,  we might not need 
to undertake SN biopsy on all patients who are found to 
have occult invasive diseases on final pathology.  If so,  
further studies are needed to determine which patients 
can forego the SN biopsy.
Our study has two limitations.  One limitation is 
inherent to any single-institutional,  retrospective study.  
The other is that several types of ultrasonography 
machines were used in this study.  In conclusion,  pre-
operative findings of ultrasonography (non-mass 
abnormalities > 2.4 cm in size),  histopathology 
(comedo type and solid type),  and clinical examina-
tions (palpable masses and bloody nipple discharge) 
were associated with potential invasion on final pathol-
ogy by multivariate analysis.  These predictors are useful 
to determine the necessity of SN biopsy for patients 
with DCIS diagnosed by breast needle biopsy.
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